UAN: 388-000-10-202-L01-P

Faculty:
JOHAN W. MOUTON, MD, PhD; Canisius Wilhelmina Hosp., Nijmegen, Netherlands.
MARKUS ZEITLINGER, MD; Med. Univ. Vienna, Vienna, Austria.
PAUL G. AMBROSE, PharmD; Ordway Res. Inst., Latham, NY.
DAVID R. ANDES, MD; Univ. of Wisconsin, Madison, WI.
URSULA THEURETZBACHER, PhD; Ctr. for Anti-Infective Agents, Vienna, Austria.
PAUL M. TULKENS, MD; Univ. Louvain, Bruxelles, Belgium.

Pharmacokinetics and Pharmacodynamics (PK/PD) have now become essential tools for determining the appropriate use of currently available anti-infective agents as well as for accelerating the development of new drugs. While this is now more and more recognized by Academia, Industry and Regulatory, there is presently a lack of training into these disciplines. The aim is to train people professionally involved in development or in the use of anti-infective drugs in the basic and applied aspects of pharmacokinetics and pharmacodynamics, showing how these sciences have emerged over the last 20 years and how their influence has grown.

Objectives:
Upon completion of this workshop, the participant should be able to:

• Discuss the clinical significance of PK/PD modeling of antimicrobials;
• Evaluate preclinical PK/PD information into clinical drug development;
• Determine PK/PD of antibacterials and antifungals;
• Assess drug exposure at the site of infection; and
• Recognize and evaluate clinical drug resistance.

Intended Audience: Infectious diseases specialists, pharmacologists, medical microbiologists, clinical drug development specialists, and others interested.
Course Level: Beginning
Prerequisites: A basic understanding of PK/PD, e.g. 50-01